

# Medesis Pharma Successfully Completes Phase I Clinical Trial of NP03

**Baillargues, January 5, 2011 - Medesis Pharma, the French based pharmaceutical company, announces the successful completion of a phase I clinical trial of NP03, a disease modifying treatment for Huntington's disease.**

The objective of this randomised, double-blind, placebo controlled study was to evaluate the tolerability of NP03 in healthy male volunteers following single and repeat administration of both 0.9mg and 1.8mg of the drug's active ingredient, lithium.

The company reported that there were no serious adverse events and that the drug was well tolerated both after single and repeat administration.

"We are very pleased with the favorable results of this phase I trial" stated Dr Jean-Claude Maurel, President and CEO of Medesis Pharma. "These results show a complete absence of side effects associated with current lithium therapies at doses above those we have shown to be active in a variety of pre-clinical models for neurodegenerative diseases. This success paves the way for our phase II and III studies in patients suffering from Huntington's disease."

## About NP03

NP03 is a combination of the active ingredient, lithium citrate, and Aonys®, a novel reverse micelle delivery formulation. Lithium is well documented as having unique neuroprotective effects in a variety of in vitro models but the toxicity associated with pharmacologically active doses has prevented clinical development of lithium formulations. Aonys® allows maintenance of pharmacological activity at doses 100 fold less than those classically administered in lithium therapy, through a unique systemic transport mechanism.

## About Huntington's Disease

Huntington's disease, chorea, or disorder (HD), is a neurodegenerative genetic disorder that affects motor coordination and leads to cognitive decline, dementia and death. There is no known cure or marketed disease modifying therapy.

## About Medesis Pharma

Medesis Pharma is a clinical stage pharmaceutical company specialising in the development of a wide range of therapeutic agents based upon propriety Aonys® drug delivery technology. Aonys® is particularly applicable to metal and oligonucleotide active ingredients.

### Contact

Peter Jackson PhD  
Medesis Pharma  
L'Orée des Mas, Les Cyprès  
Avenue du Golf  
34670 Baillargues  
France  
Tel. +33 (0)4 67 10 71 61  
Fax. +33 (0)4 67 72 26 21